BUPRENORPHINE ADHERENCE TRAJECTORIES, PERSISTENCE, AND HEALTHCARE EXPENDITURES AMONG COMMERCIALLY INSURED PATIENTS WITH OPIOID USE DISORDER

被引：0
|
作者：
Olateju, O. [1 ]
Thornton, J. D. [2 ]
机构：
[1] Univ Houston, Houston, TX USA
[2] Univ Houston, Coll Pharm, Houston, TX USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCR149
引用
收藏
页码：S323 / S324
页数：2
相关论文
共 50 条
  • [1] Treatment Persistence Among Insured Patients Newly Starting Buprenorphine/Naloxone for Opioid Use Disorder
    Shcherbakova, Natalia
    Tereso, Gary
    Spain, Jacqueline
    Roose, Robert J.
    ANNALS OF PHARMACOTHERAPY, 2018, 52 (05) : 405 - 414
  • [2] Buprenorphine adherence and illicit opioid use among patients in treatment for opioid use disorder
    Bhatraju, Elenore P.
    Radick, Andrea C.
    Leroux, Brian G.
    Kim, Theresa W.
    Samet, Jeffrey H.
    Tsui, Judith I.
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2023, 49 (04): : 511 - 518
  • [3] Trajectories of Preexposure Prophylaxis Adherence Among Commercially Insured Individuals
    Unigwe, Ikenna
    Goodin, Amie
    Lo-Ciganic, Wei-Hsuan
    Cook, Robert L.
    Park, Haesuk
    CLINICAL INFECTIOUS DISEASES, 2024, 78 (05) : 1272 - 1275
  • [4] Predicting buprenorphine adherence among patients with opioid use disorder in primary care settings
    Stephanie A. Hooker
    Colleen Starkey
    Gavin Bart
    Rebecca C. Rossom
    Sheryl Kane
    Anthony W. Olson
    BMC Primary Care, 25 (1):
  • [5] An explainable machine learning framework for predicting the risk of buprenorphine treatment discontinuation for opioid use disorder among commercially insured individuals
    Al Faysal J.
    Noor-E-Alam M.
    Young G.J.
    Lo-Ciganic W.-H.
    Goodin A.J.
    Huang J.L.
    Wilson D.L.
    Park T.W.
    Hasan M.M.
    Computers in Biology and Medicine, 2024, 177
  • [6] Adherence to Buprenorphine Treatment in Opioid Use Disorder
    Williams, Ted D.
    Sumner, Michael
    Dixit, Shailja
    Urbaniak, Dennis
    AMERICAN JOURNAL ON ADDICTIONS, 2022, 31 (04): : 278 - 278
  • [7] COMPARISON OF HEALTHCARE RESOURCE UTILIZATION (HCRU) AND EXPENDITURES AMONG US COMMERCIALLY-INSURED PATIENTS WITH OPIOID USE DISORDER (OUD) BY TYPE OF MEDICATION-ASSISTED TREATMENT (MAT) RECEIVED
    Perry, A.
    Wing, V
    Manjelievskaia, J.
    VALUE IN HEALTH, 2019, 22 : S692 - S693
  • [8] Treatment of Opioid Use Disorder Among Commercially Insured Patients in the Context of the COVID-19 Pandemic
    Huskamp, Haiden A.
    Busch, Alisa B.
    Uscher-Pines, Lori
    Barnett, Michael L.
    Riedel, Lauren
    Mehrotra, Ateev
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (23): : 2440 - 2442
  • [9] Early Discontinuation of Buprenorphine Therapy for Opioid Use Disorder Among Privately Insured Adults
    Agbese, Edeanya
    Leslie, Douglas L.
    Manhapra, Ajay
    Rosenheck, Robert
    PSYCHIATRIC SERVICES, 2020, 71 (08) : 779 - 788
  • [10] Quality of Buprenorphine Care for Insured Adults With Opioid Use Disorder
    Anderson, Kelly E.
    Saloner, Brendan
    Eckstein, Julia
    Chaisson, Christine E.
    Scholle, Sarah H.
    Niles, Lauren
    Dy, Sydney
    Alexander, G. Caleb
    MEDICAL CARE, 2021, 59 (05) : 393 - 401
12345